Literature DB >> 28337384

Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity?

Fengzhi Li1, Xiang Ling2, Danni L Harris3, Jianqun Liao2, Yuping Wang4, David Westover5, Guohui Jiang6, Bo Xu7, Patrick M Boland8, Chunyang Jin3.   

Abstract

FL118 is a novel camptothecin (CPT) analogue that possesses exceptional antitumor efficacy in human tumor animal models. To date, two CPT analogues, irinotecan and topotecan, have been approved by the FDA for cancer treatment. FL118 exhibits superior antitumor activity over irinotecan and topotecan, and effectively overcomes the irinotecan- or topotecan-resistant human tumors in animal models. Accordingly, FL118 selectively inhibits the expression of multiple cancer-associated proteins (survivin, Mcl-1, XIAP, cIAP2, MdmX). However, FL118 has hematopoietic toxicity similar to irinotecan and topotecan, suggesting that FL118's hematopoietic toxicity may share a mechanism similar to irinotecan and topotecan. It is known that CPTs including irinotecan, SN-38 (active metabolite of irinotecan) and topotecan are topoisomerase I (Top1) inhibitors. However, the evidence from our studies failed to reveal that FL118 is a better Top1 inhibitor than SN-38. It was documented that Top1 expression level is positively associated with CPTs' sensitivity. Low Top1 expression links to CPTs' resistance. In contrast to these findings, we found that human colorectal tumor sensitivity to FL118 is irrelevant to the expression level of Top1 protein. FL118 can show high antitumor efficacy in Top1-negative tumors, while Top1 highly positive tumors can exhibit FL118 resistance. This suggests that the presence of Top1 target is not critical for FL118 antitumor activity. In other words, targeting Top1 by FL118 may not play a major role for its antitumor efficacy. However, studies indicate that FL118 can bind to, and inhibit Top1 activity. This raises the possibility that inhibition of Top1 by FL118 may predominantly be involved in hematopoietic toxicity, but not in FL118 antitumor activity. In this article, we will summarize existing observations and provide our up-to-date research results to support our opinion on this important topic.

Entities:  

Keywords:  FL118; Mcl-1; MdmX; XIAP; cIAP2; camptothecin; irinotecan; survivin; topoisomerase I; topotecan

Year:  2017        PMID: 28337384      PMCID: PMC5336509     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  41 in total

1.  The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support?

Authors:  N Cacciari; C Zamagni; A Martoni
Journal:  Eur J Gynaecol Oncol       Date:  2000       Impact factor: 0.196

2.  The mechanism of topoisomerase I poisoning by a camptothecin analog.

Authors:  Bart L Staker; Kathryn Hjerrild; Michael D Feese; Craig A Behnke; Alex B Burgin; Lance Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

3.  MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.

Authors:  Asao Sakai; Kazuo Kasahara; Tohru Ohmori; Hideharu Kimura; Takashi Sone; Masaki Fujimura; Shinji Nakao
Journal:  J Thorac Oncol       Date:  2012-09       Impact factor: 15.609

4.  Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.

Authors:  Richard A Friesner; Robert B Murphy; Matthew P Repasky; Leah L Frye; Jeremy R Greenwood; Thomas A Halgren; Paul C Sanschagrin; Daniel T Mainz
Journal:  J Med Chem       Date:  2006-10-19       Impact factor: 7.446

Review 5.  Topoisomerase I inhibitors: camptothecins and beyond.

Authors:  Yves Pommier
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

6.  P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice.

Authors:  Michael Tagen; Yanli Zhuang; Fan Zhang; K Elaine Harstead; Jun Shen; Paula Schaiquevich; Charles H Fraga; John C Panetta; Christopher M Waters; Clinton F Stewart
Journal:  Drug Metab Lett       Date:  2010-12

7.  P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.

Authors:  Nienke A de Vries; Jin Zhao; Emily Kroon; Tessa Buckle; Jos H Beijnen; Olaf van Tellingen
Journal:  Clin Cancer Res       Date:  2007-11-01       Impact factor: 12.531

8.  Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro.

Authors:  Peter J Houghton; Glen S Germain; Franklin C Harwood; John D Schuetz; Clinton F Stewart; Elisabeth Buchdunger; Peter Traxler
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

9.  A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.

Authors:  Xiang Ling; Shousong Cao; Qiuying Cheng; James T Keefe; Youcef M Rustum; Fengzhi Li
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

10.  FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance.

Authors:  David Westover; Xiang Ling; Hong Lam; Jacob Welch; Chunyang Jin; Celine Gongora; Maguy Del Rio; Mansukh Wani; Fengzhi Li
Journal:  Mol Cancer       Date:  2015-04-28       Impact factor: 27.401

View more
  10 in total

Review 1.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Authors:  Fengzhi Li; Tao Jiang; Qingyong Li; Xiang Ling
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

2.  FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy.

Authors:  Xiang Ling; Wenjie Wu; Ieman A M Aljahdali; Jianqun Liao; Sreevidya Santha; Christos Fountzilas; Patrick M Boland; Fengzhi Li
Journal:  Clin Transl Med       Date:  2022-05

3.  Lipid-derived electrophiles mediate the effects of chemotherapeutic topoisomerase I poisons.

Authors:  Amy Flor; Donald Wolfgeher; Jing Li; Leslyn A Hanakahi; Stephen J Kron
Journal:  Cell Chem Biol       Date:  2020-12-21       Impact factor: 9.039

Review 4.  Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study?

Authors:  Fengzhi Li; Ieman Aljahdali; Xiang Ling
Journal:  J Exp Clin Cancer Res       Date:  2019-08-22

5.  Grouped-seq for integrated phenotypic and transcriptomic screening of patient-derived tumor organoids.

Authors:  Yushuai Wu; Kaiyi Li; Yaqian Li; Tao Sun; Chang Liu; Chunhui Dong; Tian Zhao; Decong Tang; Xiaojie Chen; Xiaofang Chen; Peng Liu
Journal:  Nucleic Acids Res       Date:  2022-03-21       Impact factor: 16.971

6.  Preparation of a camptothecin analog FLQY2 self-micelle solid dispersion with improved solubility and bioavailability.

Authors:  Yi Wang; Wenchao Wang; Endian Yu; Wenya Zhuang; Xuanrong Sun; Hong Wang; Qingyong Li
Journal:  J Nanobiotechnology       Date:  2022-09-05       Impact factor: 9.429

7.  Camptothecin exhibits topoisomerase1-independent KMT1A suppression and myogenic differentiation in alveolar rhabdomyosarcoma cells.

Authors:  David W Wolff; Min-Hyung Lee; Mathivanan Jothi; Munmun Mal; Fengzhi Li; Asoke K Mal
Journal:  Oncotarget       Date:  2018-05-25

8.  An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer.

Authors:  Xiang Ling; Wenjie Wu; Chuandong Fan; Chao Xu; Jianqun Liao; Laurie J Rich; Ruea-Yea Huang; Elizabeth A Repasky; Xinjiang Wang; Fengzhi Li
Journal:  J Exp Clin Cancer Res       Date:  2018-10-03

9.  Synthesis and biological activities of two camptothecin derivatives against Spodoptera exigua.

Authors:  Fulai Yang; Liping Wang; Lan Zhang; Yanning Zhang; Liangang Mao; Hongyun Jiang
Journal:  Sci Rep       Date:  2019-12-02       Impact factor: 4.379

Review 10.  Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma.

Authors:  Ieman A M Aljahdali; Renyuan Zhang; Fengzhi Li; Kent L Nastiuk; John J Krolewski; Xiang Ling
Journal:  J Exp Clin Cancer Res       Date:  2021-08-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.